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Translation termination is signaled by three stop 
codons: UAA, UAG, and UGA. This mechanism 
is highly conserved, although each stop codon 
has a different efficiency for terminating trans-
lation. UGA is considered to be a “leaky” stop 
codon with the highest intrinsic readthrough 
potential. UAA shows high fidelity and little 
intrinsic readthrough potential, whereas UAG 
has intermediate fidelity (Weiner and Weber, 
1973; Lovett et al., 1991). Nonsense mutations 
create primary premature termination codons 
(PTCs) and result in either no formation of 
the target protein or truncated protein with 
impaired stability.
Certain compounds influence the fidelity of 
stop codon recognition and induce readthrough 
of primary PTCs, which allows translation of 
some full-length protein. In many cases, the 
readthrough-induced protein is functional, even 
when it contains a wrongly incorporated amino 
acid (Keeling and Bedwell, 2005; Zingman   
et al., 2007).
It is estimated that 30% of human disease-
causing alleles are nonsense mutations (Mendell 
and Dietz, 2001). Other types of mutation, such 
as frameshift and splicing mutations, lead to sec-
ondary PTCs; however, these are not therapeu-
tic targets for readthrough compounds (RTCs). 
Considering that >1,800 distinct genetic disorders 
are caused by nonsense mutations, the readthrough 
of primary PTCs has treatment potential for 
large numbers of patients.
To date, most reported PTC-RTCs that are 
active in mammalian cells have belonged to the 
aminoglycoside antibiotics class (Keeling and 
Bedwell, 2005; Zingman et al., 2007). Certain 
types of aminoglycosides can induce ribosomes 
to read through PTC mutations via insertion of 
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Large numbers of genetic disorders are caused by nonsense mutations for which compound-
induced readthrough of premature termination codons (PTCs) might be exploited as a 
potential treatment strategy. We have successfully developed a sensitive and quantitative 
high-throughput screening (HTS) assay, protein transcription/translation (PTT)–enzyme-
linked immunosorbent assay (ELISA), for identifying novel PTC-readthrough compounds 
using ataxia-telangiectasia (A-T) as a genetic disease model. This HTS PTT-ELISA assay is 
based on a coupled PTT that uses plasmid templates containing prototypic A-T mutated 
(ATM) mutations for HTS. The assay is luciferase independent. We screened 34,000 
compounds and identified 12 low-molecular-mass nonaminoglycosides with potential PTC-
readthrough activity. From these, two leading compounds consistently induced functional 
ATM protein in ATM-deficient cells containing disease-causing nonsense mutations, as 
demonstrated by direct measurement of ATM protein, restored ATM kinase activity, and 
colony survival assays for cellular radiosensitivity. The two compounds also demonstrated 
readthrough activity in mdx mouse myotube cells carrying a nonsense mutation and in-
duced significant amounts of dystrophin protein.
©  2009  Du  et  al.  This  article  is  distributed  under  the  terms  of  an  Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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compounds. They further establish that enhanced PTC 
readthrough can be considered as a therapeutic strategy for 
correcting nonsense mutations in many genetic diseases.
RESULTS
Development and validation of HTS assay PTT-ELISA
In vitro PTT was originally designed to detect truncating 
mutations (Roest et al., 1993; Telatar et al., 1996). ELISA 
was coupled into PTT to improve throughput for the detec-
tion of these mutations (Gite et al., 2003; L. Du et al., 2008). 
In a previous study, we used a PTT-PAGE gel approach to 
evaluate various aminoglycosides for readthrough activity of 
ATM nonsense mutations (Lai et al., 2004). However, the 
gel-based PTT assay was time consuming and involved the 
use of radioactive material; thus, it was difficult to automate 
for a high-throughput format. Herein, we have developed a 
plasmid-driven PTT-ELISA assay for screening large num-
bers of compounds for PTC readthrough activity. The assay 
uses plasmid templates containing prototypic ATM mutations, 
patterned after specific disease-causing ATM mutations. So as 
to work in a mammalian system, rabbit reticulocytes were 
chosen to drive the PTT reaction. Various fragments of mu-
tated ATM alleles from cells of A-T patients were cloned into 
the plasmids and were N- and C-terminally tagged with the 
epitopes myc and V5, respectively. Anti-myc antibody was 
used to capture the translated protein onto an ELISA plate. If 
compounds induce PTC-readthrough in the assay, the plas-
mid-driven PTT results in a full-length ATM fragment in-
cluding the V5 tag, which is detected with anti–V5–horseradish 
peroxidase (HRP) antibody (Fig. 1 a).
We  constructed  three  mutant  plasmids  that  contain   
prototypic PTC mutations in the ATM gene from three 
different A-T patients. The plasmid used for preliminary screen-
ing, plasmid-TAT51, contains ATM region 5 fragment (co-
dons 1403–1886) and harbors a nonsense (PTC) mutation 
(c.5623C→T) that leads to a TGA C stop codon. The second 
mutant plasmid, plasmid-AT153LA, contains the same TGA 
stop  codon  but  at  a  different  position  within  the  gene 
(c.8977C→T) in region 8 (codons 2550–3050) and also has a 
different +4 nt (TGA A). This was used to monitor the effect 
of surrounding sequences of PTCs on readthrough ability. A 
third mutant plasmid, plasmid-AT185LA, contains a different 
stop codon, TAA G, resulting from a nonsense mutation 
(c.3673C→T) in region 4 (codons 1041–1531). Plasmids 
containing the same fragments but without mutations were 
constructed by in vitro mutagenesis of patient-derived com-
plementary DNA and were used as wild-type controls.
We first evaluated the specificity and sensitivity of PTT-
ELISA to detect the in vitro–translated full-length protein 
fragment. All three mutant plasmids gave only background 
signal, whereas the comparable wild-type plasmids showed 
signals greater than 200-fold over background (Fig. 1 b, top), 
indicating that the assay specifically recognized full-length 
protein fragments. We next used TAT51 wild-type plasmid 
to evaluate the sensitivity of the assay. The TAT51 wild-type 
plasmid was serially diluted with TAT51 mutant plasmid and 
a random amino acid by near-cognate transfer RNA. The 
therapeutic potential of aminoglycosides has been evaluated in 
the laboratory for different genetic models, such as cystic fi-
brosis (Howard et al., 1996; Bedwell et al., 1997; Du et al., 
2002), muscular dystrophy (Howard et al., 2000; Wagner et al., 
2001; Dunant et al., 2003; Loufrani et al., 2004), Hurler syn-
drome (Keeling et al., 2001), cystinosis (Helip-Wooley et al., 
2002), spinal muscular atrophy (Sossi et al., 2001), ataxia-
telangiectasia (A-T; Lai et al., 2004), and type 1 Usher syndrome 
(Rebibo-Sabbah et al., 2007). Clinical trials also indicate that 
aminoglycosides can induce some functional protein produc-
tion; however, the therapeutic benefits remain uncertain 
(Wilschanski et al., 2000; Clancy et al., 2001; Wagner et al., 
2001; Politano et al., 2003). Furthermore, the toxicity of most 
commercial aminoglycosides in mammals has greatly dimin-
ished  their  potential  for  successful  readthrough  therapy   
(Mingeot-Leclercq and Tulkens, 1999; Guan et al., 2000). 
Therefore, efforts are underway to develop better aminogly-
coside derivatives with reduced toxicity and enhanced activity 
(Nudelman et al., 2006; Rebibo-Sabbah et al., 2007). Re-
cently, PTC Therapeutics (South Plainfield, NJ) described a 
more  efficient  nonaminoglycoside  RTC,  PTC124,  which 
was developed synthetically by screening >800,000 chemicals 
and  analogues  using  a  luciferase-based  high-throughput 
screening (HTS) assay (Welch et al., 2007; Hirawat et al., 
2007; M. Du et al., 2008). A phase-I clinical study in cystic 
fibrosis confirmed that PTC124 is generally well tolerated and 
appears to have more efficient readthrough activity than ami-
noglycosides (Hirawat et al., 2007). Moreover, PTC124 does 
not induce ribosomal readthrough of normal stop codons. A 
phase-II clinical trial is underway (Kerem et al., 2008). How-
ever,  a  recent  study  indicates  that  the  initial  discovery  of 
PTC124 by HTS may have been biased by its direct effect on 
the FLuc (firefly luciferase) reporter used (Auld et al., 2009), 
indicating the importance of a luciferase-independent HTS 
assay for future drug screening.
In an effort to discover new RTCs, we developed a sen-
sitive  and  quantitative  luciferase-independent  HTS  assay, 
protein transcription/translation (PTT)–ELISA. The PTT-
ELISA assay was validated for a fully automated 384-well ro-
botic platform and used to screen 34,000 compounds. We 
focused followup efforts on 12 low-molecular-mass non-
aminoglycoside compounds. From there, we identified two 
compounds that induced low levels of full-length functional 
A-T mutated (ATM) protein in A-T cells carrying ATM 
nonsense mutations, as demonstrated by direct measurement 
of ATM protein using ATM-ELISA, ATM-Ser1981 auto-
phosphorylation, trans-phosphorylation of structural main-
tenance  of  chromosome  (SMC)  1–Ser966,  and  colony 
survival assay (CSA). Both compounds also showed PTC-
readthrough activity in mdx mouse myotube cells carrying a 
nonsense mutation and induced significant amounts of dys-
trophin protein.
Collectively, these studies provide the first robust lucifer-
ase-independent HTS assay for identifying RTCs and proof 
of principle for PTC readthrough by nonaminoglycoside JEM VOL. 206, September 28, 2009 
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(40 nM–10 µM; Fig. 1 c). Moreover, G418 showed obvious 
toxicity for the PTT reaction at concentrations >2.5 µM, whereas 
gentamicin toxicity was not observed until 12.5 µM. These 
results are consistent with our previously published S35-PTT 
gel data (Lai et al., 2004) and demonstrate that the PTT-ELISA 
readily identifies compounds with readthrough activity.
We next validated the assay for use in a fully automated 
384-well robotic platform, using plasmid-TAT51 (TGA C) 
as  readthrough  template  and  1  µM  G418  as  the  positive 
readthrough control. To further reduce the cost of the assay, 
we optimized a decrease in the PTT reaction volume from 
25 to 5 µl. As shown in Fig. 1 d, the wells containing G418 
used to drive PTT reactions. The sample containing 1.2% of 
wild-type plasmid (2/158 ng) still gave signal that was two-
fold higher than that of mutant plasmid (Fig. 1 b, bottom), es-
tablishing the sensitivity of the assay at 1%. The sensitivity 
of an HTS assay is especially important for RTC screening be-
cause all RTCs to date have been only weak PTC readthrough 
inducers, and new classes of RTCs are expected only to be 
identified with a highly sensitive screening assay.
Next, we used two well known RTCs, G418 and genta-
micin, to test the efficiency of the PTT-ELISA assay. Both 
compounds showed significant PTC readthrough activity with 
TAT51 mutant plasmid (TGA C) over a large dose range   
Figure 1.  HTS PTT-ELISA assay for RTCs screening. (a) Schematic of PTT-ELISA HTS. ATM regions containing a PTC mutation were cloned into plas-
mids and tagged with c-myc and V5 epitopes at each end. Compounds with PTC readthrough activity induce full-length protein, which can be identified 
by anti–V5-HRP. (b) Specificity and sensitivity of PTT-ELISA. All three mutant plasmids showed only background readings, whereas wild-type plasmids 
showed signals >200-fold over background (P < 0.0001), indicating that the assay specifically detects full-length proteins. The sample containing 2 ng of 
wild-type plasmid still gave signals that were twofold higher than those of mutant plasmid alone (P < 0.01), indicating that the sensitivity of the assay is 
1% (2/158 ng). Error bars indicate the variation of duplicate samples. (c) Assay evaluation using aminoglycosides. Both G418 and gentamicin induced 
significant PTC readthrough over a large dose range. (d) Readings for a sample row from a 384-well plate. Samples containing G418 exhibited signifi-
cantly different signal (Z factor > 0.6) over the no-drug wells (P < 0.0001). ****, P < 0.0001, as compared with control. Experiments were repeated three 
times for b and c and five times for d.2288 HIGH THROUGHPUT SCREENING OF READTHROUGH COMPOUNDS | Du et al.
#14). Cells treated with the highest RTC concentrations still 
had >70% viability as compared with untreated cells. RTC#13 
and  #14  consistently  induced  low  but  detectable  levels  of 
ATM protein in A-T LCLs (Fig. 3 a). The restored ATM pro-
tein was ≤5% of the wild-type LCLs. Gentamicin and G418 
also induced small amounts of ATM protein (Fig. 3 a). We 
were encouraged by these results because A-T patients with 
some residual ATM protein levels can have substantial ATM 
kinase activity, and this has been sometimes associated with a 
later onset and slower progression of symptoms (Gilad et al., 
1998; Chun et al., 2003). Thus, we believe that even modest 
increases in ATM protein levels have therapeutic potential.
To evaluate the function of RTC-induced ATM protein, 
we measured irradiation-induced foci (IRIF) formation of 
ATM-Ser1981 in the same AT153LA cells (TGA A). A-T 
cells do not form post–ionizing radiation (IR) ATM-Ser1981 
foci because ATM protein is either absent or functionally 
impaired (usually the former). We found that RTC#13 and 
#14 induced considerable numbers of ATM-Ser1981 IRIFs 
in A-T cells with TGA A, whereas only a background level 
of IRIFs was observed in the untreated controls (Fig. 3 b). At 
same time, 51% of wild-type cells showed distinct post-IR 
foci. The maximum IRIF induction achieved in A-T cells by 
10 µM RTC#13 was 40% of wild-type level. As a positive 
readthrough control, 144 µM of G418 (100 µg/ml) was used 
to treat cells. Our previous studies had shown that, at this 
concentration, G418 induced a maximum level of ATMs1981 
IRIF (Lai et al., 2004). As anticipated, significant IRIFs were 
induced in G418-treated cells. The level in A-T cells was 
about half that in wild-type cells. The compounds were also 
tested in another A-T cell line, AT229LA, with homozygous 
TAG A mutations, and both RTC#13 and #14 induced sig-
nificant numbers of ATM-Ser1981 IRIF, as compared with 
nontreated A-T cells (Fig. 3 c).
To further compare the readthrough activity of RTC#13 
and #14 with gentamicin and G418, we used a flow cytometry 
(FC)–based ATM-Ser1981 phosphorylation assay to assess 
readthrough activity in AT229LA cells (TAG A; Fig. 4). Both 
RTC#13 and #14 induced increased ATM-Ser1981 auto-
phosphorylation, as indicated by the right shift of fluorescence 
intensity (FI). This was consistent with previous ATM IRIF 
data (Fig. 3 c). Encouragingly, ATM-Ser1981 phosphorylation 
levels induced by RTC#13 and #14 were similar to those in-
duced by the same concentrations of gentamicin and G418 in 
the same cell line (Fig. 4). Neither of the two compounds 
produces green autofluorescence (isotype controls; Fig. 4, 
top right histogram). Similar readthrough effects were also 
observed in AT153LA cells (TGA A) using cytometry-based 
ATM-Ser1981 phosphorylation assay (unpublished data).
RTC-induced restoration of SMC1-Ser966 phosphorylation 
in A-T LCLs
As an alternative assay to assess ATM kinase function, we used 
a recently developed FC-based assay to measure the trans-
phosphorylation of SMC1 in A-T LCLs (Fig. 5; Nahas et al., 
2009). ATM phosphorylates SMC1 at Ser966 and Ser957   
exhibited significantly different signals (Z factor > 0.8) over 
the no-drug wells. The fully automated assay also showed 
consistent plate-to-plate accuracy and efficiency, indicating 
the suitability of the assay for HTS (unpublished data).
Screening of chemical libraries for RTCs
About 34,000 compounds were screened to discover novel 
RTCs. Plasmid-TAT51 (TGA C) was used for the initial 
screening. Each compound was screened at a final concen-
tration of 10 µM in the assay mixture. For each screening 
plate, we included both positive (with 1 µM G418) and 
negative (with DMSO) samples as quality controls. Samples 
with signal >2-fold over the negative control were scored as 
potential “hits.” Our initial screens yielded 12 low-molecu-
lar-mass RTCs with appreciable readthrough activity. All 12 
hits were then confirmed by manual PTT-ELISA at multiple 
concentrations (chemical names shown in Table S1). None 
of them were aminoglycosides and none of them had been 
previously reported. The chemical names and structures of 
the two leading compounds, RTC#13 and #14, are shown 
in Fig. 2 a; the names and structures for the remaining 10 
RTCs are given in Fig. S1 and Table S1.
The EC50 of five compounds (RTC#4, #11, #13, #14, 
and #16) were <10 µM (Fig. 2 b, RTC#13 and #14), imply-
ing therapeutic potential of those compounds. Notably, in 
these initial cell-free experiments, the maximum in vitro 
readthrough effect for the new compounds was not as favor-
able as that of G418 or gentamicin. For example, the maxi-
mum readthrough activity of RTC#13 and #14, detected by 
the cell-free PTT-ELISA assay, was 10% of the maximum 
activity of G418 and gentamicin in the same assay (Fig. 1 c vs. 
Fig. 2 b). This may be related to the solubility, permeability, 
or toxicity of the compounds. In contrast, both RTC#13 and 
#14 had an EC50 <10 µM, they were less toxic, and they did 
not show obvious inhibition of PTT at high concentrations 
(>50 µM), unlike both G418 and gentamicin (Fig. 1 c).
The readthrough efficiency of these compounds was also 
tested on two other stop codon contexts, TGA A and TAA 
G. For TGA A, all 12 compounds showed various extents of 
readthrough  activity  (unpublished  data).  For  TAA  G,  six 
compounds  (RTC#10,  #11,  #13,  #14,  #16,  and  #17) 
showed appreciable activity (unpublished data). The data for   
RTC#13 and #14 are shown in Fig. 2 c.
RTC-induced ATM protein and ATM-Ser1981 
phosphorylation in A-T lymphoblastoid cell lines (LCLs)
To test whether the newly identified compounds could induce 
ATM protein in A-T cells with PTC mutations, we exposed 
A-T LCLs to each compound for 4 d before harvesting the 
cells. Western blotting of nuclear lysates was generally of insuf-
ficient sensitivity for monitoring RTC-induced ATM protein 
(Lai et al., 2004); therefore, we used an ATM-ELISA method 
to measure intranuclear ATM protein in cells (Butch et al., 
2004). Concentrations of individual RTCs used to treat 
AT153LA LCL with a homozygous TGA A mutation were 
based on their cytotoxicity profile (Fig. S2, RTC#13 and JEM VOL. 206, September 28, 2009 
ARTICLE
2289
RTC-induced correction of SMC1 phosphorylation was dose 
dependent in AT153LA cells (TGA A; Fig. S3).
RTC-induced restoration of ATM kinase in A-T fibroblast cells
To determine whether the two lead RTCs were also active 
in other types of cells, we tested them against the A-T fibro-
blast cell line GM02052, which contains a homozygous TGA 
G mutation (c. 103C→T). RTC-treated cells showed slightly 
increased IR-induced SMC1-Ser966 (Fig. 6 a) and ATM-
Ser1981 phosphorylation (Fig. 6 b), as compared with untreated 
after IR-induced double-strand breaks (Yazdi et al., 2002; 
Kitagawa et al., 2004), and IR-induced SMC1 phosphoryla-
tion is deficient in A-T cells. In untreated AT153LA cells 
(TGA A), we observed no phosphorylation of SMC1 (Fig. 5 a, 
top, left). After treatment with either RTC#13 or #14, a 
right shift in FI was observed, indicating restored ATM kinase 
activity. Both G418 and gentamicin induced SMC1 phos-
phorylation in A-T cells at similar levels. We also tested the 
same compounds on TAG A mutation using AT229LA cells. 
They all induced detectable SMC1 phosphorylation (Fig. 5 b). 
Figure 2.  Two leading RTCs were identified by HTS. (a) Molecular structures of RTC#13 and #14 (2-imino-5-{[5-(2-nitrophenyl)-2-furyl]methylene}-
1,3-thiazolidin-4-one and 4-tert-butyl-2-[(3-nitrobenzylidene)amino]pheno). (b) TGA C readthrough activity by PTT-ELISA. (c) TGA A and TAA G readthrough 
activity. **, P < 0.01; ***, P < 0.001, as compared with untreated control. Experiments were repeated four times for b and three times for c.2290 HIGH THROUGHPUT SCREENING OF READTHROUGH COMPOUNDS | Du et al.
RTC-induced cell survival correction in A-T LCLs
Because  the  radiosensitivity  of  A-T  cells  results  from  the 
ATM deficiency, we next investigated whether RTC#13 
and #14 can abrogate A-T cell’s radiosensitivity of A-T cells. 
cells. As positive readthrough controls, gentamicin and G418 
showed readthrough activities similar to RTC#13 and #14 
at  the  concentrations  compared,  indicating  that  both 
RTC#13 and #14 were also active on A-T fibroblasts.
Figure 3.  RTCs induced intranuclear ATM protein and post-IR ATM-Ser1981 foci in A-T LCLs. LCLs were treated with compound for 4 d before 
harvesting. Induced ATM protein was assessed by ATM-ELISA and ATM-Ser1981 IRIF. For IRIF test, cells were irradiated with 2 Gy and IRIFs were scored 
after 30 min. All experiments were repeated three times. (a) Cells treated with various doses of compound RTC#13 and #14 showed a significantly in-
creased ATM protein level, as compared with nontreated A-T samples (P < 0.05). The dashed line indicates the basal ATM protein level in untreated A-T 
cells. (b) RTC-induced ATM-Ser1981 IRIF in AT153LA (TGA A) cells. (c) RTC-induced ATM-Ser1981 IRIF in AT229LA (TAG A) cells. *, P < 0.05; **, P < 0.01, as 
compared with untreated sample. Error bars indicate the variation of two independent experiments.JEM VOL. 206, September 28, 2009 
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Figure 4.  RTCs induced FC-ATM-Ser1981 phosphorylation in A-T LCLs. AT229LA cells (TAG A) were treated with RTC#13 and #14 for 4 d and 
analyzed for ATM-Ser1981 phosphorylation using FC. Gentamicin and G418 were used as positive readthrough controls. All compounds induced ATM 
phosphorylation in A-T cells, as indicated by a right FI shift. Neither compound produced autofluorescence, as shown in the top right histogram. Results 
were consistent in three independent experiments.2292 HIGH THROUGHPUT SCREENING OF READTHROUGH COMPOUNDS | Du et al.
myotubes. The mdx mouse has been widely used as a model 
for Duchenne muscular dystrophy. It carries a C to T transi-
tion in exon 23 of the dystrophin gene that creates a prema-
ture stop codon (TAA), resulting in an absence of dystrophin 
protein (Sicinski, et al., 1989). Because gentamicin has been 
shown to induce readthrough of the mdx PTC mutation and 
to restore dystrophin expression in mdx mice both in vitro 
and in vivo (Barton-Davis, et al., 1999), we used it as a posi-
tive readthrough control in the experiments. Muscle progen-
itor cells isolated from mdx mice were induced to differentiate 
for 24 h before addition of gentamicin or compounds RTC#13 
and #14. Myotube cultures were exposed to compounds for 
72 h and then analyzed for dystrophin by Western blotting. 
Full-length dystrophin was clearly detected in cells treated 
with RTC#13 and #14 at concentrations of 10 and 20 µM 
but not in cultures treated with gentamicin at concentrations 
of 20 µM (unpublished data). We next used immunoprecipi-
tation to increase the sensitivity of the assay (Fig. 8). Dystro-
phin expression was present in cells treated with gentamicin 
at concentrations of 20 and 100 µM. Both of our lead com-
pounds showed readthrough activity, inducing significant 
AT153LA cells (TGA A) were treated with compounds for   
4 d and followed by CSA. One wild-type cell line and one 
different A-T cell line were used as assay quality controls. As 
expected, the wild-type and A-T controls showed 49 and 
11% survival fraction, respectively. These were within the 
normal (>36%) and radiosensitive (<21%) range, respectively 
(Fig. 7, right two bars). Untreated AT153LA cells showed a 
13.5% survival fraction, which is radiosensitive (Fig. 7, left 
bar). Encouragingly, we found that both RTC#13 and #14 
(at 10 and 20 µM) abrogated AT153LA cell radiosensitivity, 
from radiosensitive (13.5%) to intermediate (21–36%) range. 
100 µM G418 also abrogated radiosensitivity to intermediate 
range, whereas gentamicin did not show a significant effect in 
this assay at the tested concentrations (10 and 20 µM). The 
definition of CSA range used was previously established 
in our laboratory and is used for clinical A-T diagnosis (see 
Materials and methods).
RTCs induced mdx PTC readthrough in mouse myotube cells
To investigate the ability of RTC#13 and #14 to readthrough 
a PTC mutation in genes other than ATM, we used mdx 
Figure 5.  RTCs induced FC-SMC1 pSer966 phosphorylation in A-T LCLs. (a) RTC#13 and #14 restored SMC Ser966 phosphorylation in AT153LA 
cells (TGA A). (b) RTC#13 and #14 restored SMC1 Ser966 phosphorylation in AT229LA cells (TAG A). All experiments were repeated three times.JEM VOL. 206, September 28, 2009 
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the effect of nonaminoglycoside RTCs on various primary 
premature stop codons. We have previously used aminogly-
cosides and antisense oligonucleotides to correct nonsense and 
splicing ATM mutations, respectively, and to restore func-
tional ATM protein in A-T LCLs (Lai et al., 2004; Du et al., 
2007). These studies suggest that therapeutic benefits might 
be achieved if even modest increases in functional ATM pro-
tein levels can be induced. In these limited studies, we saw no 
significant effects on efficiency of readthrough from the fourth 
nucleotide of each tested stop codon.
Herein, we successfully developed a sensitive luciferase-
independent HTS assay by coupling PTT and ELISA. PTT-
ELISA shows high specificity for detecting readthrough 
products and, thus, minimizes false positives in the initial 
large-scale library screening. The assay is also very sensitive; 
the minimum detection threshold is 1%, which ensures its 
efficiency as a HTS assay. The efficiency of PTT-ELISA was 
further evaluated using two well known RTCs, G418 and 
gentamicin. The assay was able to detect their readthrough 
amount of dystrophin protein. Results were consistent in 
multiple experiments performed.
DISCUSSION
We believe that HTS can identify new nonaminoglycoside 
RTCs with therapeutic potential. In this study, we used A-T 
as a disease model to identify new RTCs. A-T is a progressive 
autosomal recessive neurodegenerative disorder resulting from 
mutations in the ATM gene (Perlman et al., 2003; Chun and 
Gatti, 2004). ATM protein plays a very important role in cell 
cycle control, DNA damage repair, the oxidative stress re-
sponse, and apoptosis (Shiloh, 2006). The A-T disorder pro-
vides an appropriate laboratory model for demonstrating novel 
principles of mutation-targeted therapy. In the ATM muta-
tion spectrum, primary nonsense mutations account for 15% 
of the unique mutations detected in A-T patients (www 
.LOVD.nl/ATM). A well characterized spectrum of ATM 
mutations, supported by an extensive library of LCLs derived 
from patients with those mutations, allowed us to investigate 
Figure 6.  RTCs restored ATM kinase activity in A-T fibroblast cells. GM02052 cells with a homozygous c.103C→T mutation (TGA G) were treated 
with RTC#13 and #14 for 4 d, and ATM kinase activity was assessed using FC-based SMC1-Ser966 phosphorylation and ATM-Ser1981 phosphorylation. 
All experiments were repeated three times. (a) Histograms of FC-SMC1-Ser966. (b) Cell population positive for ATM-Ser1981 staining. The dashed line 
indicates the basal ATM s1981 phosphorylation in the nontreated A-T cells after radiation (10 Gy). **, P < 0.01, as compared with untreated sample. Error 
bars indicate the variation of two independent experiments.2294 HIGH THROUGHPUT SCREENING OF READTHROUGH COMPOUNDS | Du et al.
PTC readthrough activity in A-T cells, both in LCLs and 
fibroblasts, as demonstrated by ATM-ELISA, ATM kinase 
activity (autophosphorylation of ATM and trans-phosphory-
lation of SMC1), and CSA. To determine whether the com-
pounds can read through PTC mutations in other genes, we 
selected mouse mdx myotube cells and tested their ability to 
induce readthrough in a different species, a different cell type 
(nondividing muscular cells), and a different premature stop co-
don (TAA). In other studies, the TAA codon has proven the 
most difficult to read through (Kimura et al., 2005; Welch 
et  al.,  2007).  Both  RTC#13  and  #14  induced  PTC 
readthrough of the mouse mdx dystrophin gene.
Collectively, our data showed that both RTC#13 and 
#14 had comparable readthrough activity in cell-based assays, 
even though their activities in cell-free PTT-ELISA assay 
were much lower than gentamicin and G418. This may be 
related to differences in cell-based metabolism, drug solubil-
ity, and permeability of compounds.
To assess the impact of the compounds on readthrough of 
normal stop codons of other proteins, we performed two-
dimensional gel electrophoresis. Neither compound signifi-
cantly interfered with protein expression patterns (Fig. S4), 
implying that these compounds have potential for further   
activity over a very large concentration range (G418, 40 nM–
10 µM; gentamicin, 40 nM–100 µM). Furthermore, PTT-
ELISA has been validated for a fully automated robotic 
platform, with consistent accuracy between plates. The 384-
well format dramatically reduced the workload for screening 
thousands of compounds and also saved time, costs, and re-
agents. Moreover, this assay has the potential to be validated 
for a 1,536-well format. For these reasons, we believe that 
the PTT-ELISA HTS assay provides a powerful new tool for 
identifying new RTCs.
From a library of 34,000 compounds, we identified 12 
low-molecular-mass  compounds  (between  300  and  450 
daltons) with PTC readthrough activity. None of these new 
compounds were aminoglycosides. Several compounds showed 
EC50 values <10 µM, implying their potential for further de-
velopment. To further assess these compounds in cell sys-
tems, we tested their readthrough activity in A-T LCLs with 
a variety of nonsense mutations. We used ATM-ELISA to 
directly detect ATM protein levels in treated cells. Subse-
quently, more sensitive cell-based assays, such as FC-based 
SMC1-Ser966, ATM-Ser1981 phosphorylation, and ATM-
Ser1981-IRIF, were used to assess restored ATM kinase ac-
tivity. Among the 12 compounds, RTC#13 and #14 showed 
Figure 7.  RTCs abrogated the radiosensitivity of A-T LCLs. AT153LA cells (TGA A) were treated with compounds and the CSA was measured. 
RTC#13, RTC#14, and G418 increased cell survival fractions to intermediate range. Gentamicin did not show an effect at tested concentrations. Results 
were consistent in three independent experiments.JEM VOL. 206, September 28, 2009 
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and  AT153LA,  homozygous  8977C→T  (TGA  A).  Reverse-transcription 
PCR was performed using custom designed primers which introduced   
N- and C-terminal epitopes (c-myc and V5, respectively) into the PCR 
products (Du et al., 2008). PCR products were then cloned into pcDNA5/
FRT/TO TOPO plasmids according to the manufacturer’s protocols (Invit-
rogen). The PCR products for each mutant were mutagenized back to nor-
mal and used as paired normal control plasmids. DNA sequencing confirmed 
the PTT fragments in all constructs.
High-throughput PTT-ELISA. Three chemical libraries, ChemBridge, 
Prestwick, and MicroSource, were used in our primary screening. The final con-
centration for each compound tested was 10 µM. Screening was performed on a 
fully integrated CORE System (Beckman Coulter). PTT was performed in a re-
action volume of 5 µl. The TNT T7 PCR Quick Master Mix, containing 20 µM 
methionine, was aliquoted into a 384-well low-volume plate (MatriCal Biosci-
ence). Compounds were added using a 384-well pin tool (V&P Scientific, Inc.). 
The PTT reaction was started by the addition of purified plasmid at 50 ng/well, 
which was incubated for 2 h at 30°C. PTT samples were subsequently stored at 
4°C for ELISA analysis. For each plate, G418 at a final concentration of 1 µM 
served as positive control and reactions with 1% DMSO served as negative con-
trol. ELISA was performed in a 384-well MaxiSorp ELISA plate (Nunc). The 
plate was coated with 20 µl of 5-µg/ml mouse anti-Myc antibody (Invitrogen) 
overnight at 4°C, followed by washing with PBS and blocking with 50 µl PB-
STM (PBS-containing 0.05% Tween-20 and 5% milk) for 30 min at 37°C. 20 µl 
H2O was added in PTT plate and 15 µl of reaction solution was transferred into 
ELISA plate, followed by overnight incubation at room temperature. After wash-
ing the plate, 20 µl of 1:500 mouse anti-V5 HRP (Invitrogen) was added and in-
cubated for 2 h at 37°C. The plate was washed, incubated with 30 µl SuperSignal 
ELISA Pico working solution (Thermo Fisher Scientific), and measured on the 
Victor-3V using “top read” and an integration time of 0.5 s.
Immunoassay  for  measurement  of  intranuclear  ATM  protein. 
Readthrough-induced full-length ATM protein in A-T cells was measured 
by ATM immunoassay (Butch et al., 2004). Cell nuclear extracts were pre-
pared using NE-PER protocol (Thermo Fisher Scientific). Then ATM-
ELISA was performed using 200-µg nuclear extracts. ATM concentrations 
of tested samples were calculated from the standard calibration curve using 
purified ATM protein (Chun et al., 2004).
Immunofluorescence of ATM-Ser1981 IRIF. Immunostaining of nu-
clear foci of ATM-Ser1981was performed as previously reported (Du et al., 
2007). In brief, after being treated with compound for 4 d, cells were irradi-
ated with 2 Gy and incubated at 37°C for 30 min. The cells were dropped 
onto coverslips, fixed with 4% paraformaldehyde, and permeabilized. Cov-
erslips were blocked for 1 h and incubated with mouse anti-ATM pSer1981 
for 1 h (1:500; Rockland Immunochemicals, Inc.). After a second blocking, 
cells were stained with FITC-conjugated anti–mouse IgG (1:150; Jackson 
ImmunoResearch Laboratories) for 1 h and mounted onto slides.
development. However, we anticipate that significant thera-
peutic effects may not be discernable in A-T patients if the 
RTC-induced ATM level is <15% of normal, and this very 
likely also applies to other genetic disorders. Therefore, fur-
ther structural modifications to improve pharmodynamics 
will be necessary. Structural optimization has improved the 
readthrough activity and lowered the toxicity of aminoglyco-
sides (Nudelman et al., 2006; Rebibo-Sabbah et al., 2007). 
Therefore, it is expected to be effective for developing better 
nonaminoglycoside readthrough analogues as well.
The underlying mechanisms of PTC readthrough activity 
for these newly identified compounds remain unknown. It 
has been demonstrated that all of the known PTC-RTCs 
function by interfering with ribosomal translation. Certainly, 
aminoglycosides interact with the decoding center of the 
ribosomal 16S subunit and cause misincorporation of an 
amino acid at the PTC site which allows translation to con-
tinue (Keeling and Bedwell, 2005; Zingman et al., 2007). 
PTC124 is believed to act at a different location on the ribo-
some (Linde and Kerem, 2008). It will be interesting to learn 
whether RTC#13 and #14 interact with the ribosome.
It has been reported that nonsense-mediated messenger 
RNA (mRNA) decay (NMD) can significantly affect RTC-
induced PTC-readthrough because mRNA transcripts carrying 
nonsense mutations are degraded by this pathway (Wilkinson 
and Shyu, 2002; Holbrook et al., 2004). Therefore, inhibition 
of NMD may stabilize mutant mRNA transcripts and in-
crease RTC-induced readthrough output (Linde et al., 2007; 
Linde and Kerem, 2008). We have examined this in our lab-
oratory using many different ATM nonsense mutations, and 
we have failed to detect a clear pattern of NMD or inhibition 
of NMD, suggesting that NMD in A-T cells may be a matter 
of degree. NMD efficiency may also vary between different 
mutations and different genes. The role of NMD in RTC-
induced treatment remains to be clarified.
MATERIALS AND METHODS
Plasmids construction. To construct plasmids containing stop codon 
mutations in their own context, we selected ATM nonsense mutations that 
resulted directly from disease-causing point mutations in A-T patients. The 
LCLs used in this study carried the following mutations: TAT51, homozy-
gous 5623C→T (TGA C); AT185LA, homozygous 3673C→T (TAA G); 
Figure 8.  RTCs restored full-length dystrophin protein in mouse mdx myotubes (TAA). Cells were prepared and treated with RTCs for 3 d. Dystro-
phin proteins were detected by Western blot analysis using immunoprecipitation. Wild-type cells were used in the experiment to localize dystrophin pro-
tein. Gentamicin was used as a positive readthrough control. Both RTC#13 and #14 induced a significant amount of dystrophin protein. Results were 
consistent in three independent experiments.2296 HIGH THROUGHPUT SCREENING OF READTHROUGH COMPOUNDS | Du et al.
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